Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
Primary Purpose
Obesity, Premature Recovery From Anesthesia
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Nuvigil
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Obesity focused on measuring Obstructive Sleep Apnea, Anesthesia Recovery Period
Eligibility Criteria
Inclusion Criteria:
- Patient presented for surgery under general anesthesia
- Documented OSA
- Patients with BMI above 35
Exclusion Criteria:
- Coronary Artery Disease or Myocardial infarcts
- Mitral valve prolapse
- Cyclosporine, contraceptive drugs
- Known allergic reaction to Modafinil or any of its products
Sites / Locations
- University of Texas Southwestern Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Nuvigil
Placebo
Arm Description
A single oral dose of Nuvigil at 150mg dose in preoperative area
A single oral placebo will be given in preoperative area
Outcomes
Primary Outcome Measures
Postoperative Care Unit (PACU) Recovery Time
Participants will be followed for the duration of PACU stay, an expected average of 3 hours.
Secondary Outcome Measures
The Aldrete Score
Aldrete score used for readiness of PACU discharge by assigning numeric values to the criteria including activity, respiration, circulation, consciousness, and color. Each criterion is rated from 0 to 2, with a maximum score of 10. Scores in the range of 9 to 10 are considered satisfactory for PACU discharge.
Full Information
NCT ID
NCT02478580
First Posted
June 8, 2015
Last Updated
December 3, 2018
Sponsor
University of Texas Southwestern Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02478580
Brief Title
Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
Official Title
The Effects of Armodafinil (Nuvigil) on Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
August 2011 (Actual)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
January 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Texas Southwestern Medical Center
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obstructive sleep apnea (OSA) and obesity is associated with increased perioperative morbidity and mortality. This group of patients is at risk of perioperative desaturations which can be worsened by perioperative sedatives and narcotics needed for surgery. OSA patients might also need to spend the night in intensive care for more frequent monitoring for any desaturations episodes especially if the patient will be requiring multiple intravenous narcotic boluses for pain control. Several studies have looked into the most appropriate way to manage these patients and some recommendations have been made to avoid outpatient surgery with close monitoring for first 24 hours after surgery specifically if patient will require intravenous postoperative narcotics.
Nuvigil (Armodafinil) is a wake promoting agent (Cephalon inc., West Chester, PA) that's FDA approved for excessive daytime sleepiness in narcolepsy, shift work sleep disorder, and obstructive sleep apnea. The precise mechanism(s) through which armodafinil (R-enantiomer) or modafinil (mixture of R- and S-enantiomers) promote wakefulness is unknown.
Nuvigil is longer acting product which is similar in action to Modafinil however is much cheaper. Nuvigil has not been previously studied for postoperative recovery. The investigators intend to study the effects of Nuvigil on postoperative recovery time and wakefulness in obstructive sleep apnea and obese patients.
Detailed Description
Modafinil has been shown to improve recovery after general anesthesia in a small pilot study which involved 30 patients. In these study, patients were given one dose of Modafinil 200mg po versus placebo after surgery when patient tolerating po with a sip of water and were discharged home. They were asked to assess their fatigue, alertness and energy level during the following 24 hrs. Modafinil was found to significantly reduce fatigue and improves feelings of alertness and energy in postoperative patients. It was concluded that patients recovering from general anesthesia can significantly benefit from Modafinil.
A more recent study looked at the perioperative use of Modafinil in 67 patients presenting for lithotripsy requiring sedation. Goal was to asses improvement in recovery compared to placebo. Patients were randomized to 4 groups 1 and 2 received midazolam/ fentanyl sedation plus Modafinil 200mg po given 1 hr before sedation versus placebo, the other two received remifentanil / propofol infusion plus Modafinil 20 mg po versus placebo. Groups were compared using the digital symbol substitution test (DSST), trail making test (TMT), observer scale of sedation and analgesia (OAA/S) and Aldrete score and they found no statistical significant difference between groups. However they measured the Verbal rating scale (VRS) scores for secondary outcome variables e.g. energy, tiredness and dizziness were also recorded before and after treatment. They concluded that Modafinil reduces patient-reported tiredness after sedation/analgesia however does not improve recovery in terms of objective measures of patient psychomotor skills.
Nuvigil is longer acting product which is similar in action to Modafinil and has not been previously studied for postoperative recovery. We intend to study the effects of Nuvigil on postoperative recovery time and wakefulness in obstructive sleep apnea patients and obese patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Premature Recovery From Anesthesia
Keywords
Obstructive Sleep Apnea, Anesthesia Recovery Period
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
67 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Nuvigil
Arm Type
Experimental
Arm Description
A single oral dose of Nuvigil at 150mg dose in preoperative area
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
A single oral placebo will be given in preoperative area
Intervention Type
Drug
Intervention Name(s)
Nuvigil
Other Intervention Name(s)
Armodafinil
Intervention Description
Patients will receive Nuvigil before the surgery
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Oral placebo
Intervention Description
Placebo will be given before surgery
Primary Outcome Measure Information:
Title
Postoperative Care Unit (PACU) Recovery Time
Description
Participants will be followed for the duration of PACU stay, an expected average of 3 hours.
Time Frame
Immediate postoperative period (up to 3 hours)
Secondary Outcome Measure Information:
Title
The Aldrete Score
Description
Aldrete score used for readiness of PACU discharge by assigning numeric values to the criteria including activity, respiration, circulation, consciousness, and color. Each criterion is rated from 0 to 2, with a maximum score of 10. Scores in the range of 9 to 10 are considered satisfactory for PACU discharge.
Time Frame
2 hours after extubation
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient presented for surgery under general anesthesia
Documented OSA
Patients with BMI above 35
Exclusion Criteria:
Coronary Artery Disease or Myocardial infarcts
Mitral valve prolapse
Cyclosporine, contraceptive drugs
Known allergic reaction to Modafinil or any of its products
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Enas Kandil, MD
Organizational Affiliation
UT Southwestern Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Texas Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-9068
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients
We'll reach out to this number within 24 hrs